Aprea Therapeutics, Inc. ( (APRE) ) has released its Q3 earnings. Here is a breakdown of the information Aprea Therapeutics, Inc. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapeutics through synthetic lethality, with its main programs being APR-1051 and ATRN-119. In its latest earnings report for the quarter ending September 30, 2025, Aprea Therapeutics highlighted a decrease in cash reserves and a continued net loss, reflecting ongoing challenges in its clinical development efforts. Key financial metrics revealed a net loss of approximately $10.1 million for the nine months ended September 30, 2025, compared to a similar loss in the previous year, with operating expenses slightly reduced due to lower research and development costs. The company also reported a decrease in cash and cash equivalents, which stood at $13.7 million, raising concerns about its ability to fund operations beyond the next twelve months without additional financing. Looking ahead, Aprea Therapeutics is actively seeking additional funding to support its operations and continue its clinical trials, while management remains focused on advancing its product candidates and exploring strategic opportunities to strengthen its financial position.